Please use this identifier to cite or link to this item:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70451Full metadata record
| ???org.dspace.app.webui.jsptag.ItemTag.dcfield??? | Value | Language |
|---|---|---|
| dc.contributor.advisor | 賴裕和 | |
| dc.contributor.author | Kai-Lin You | en |
| dc.contributor.author | 游鎧璘 | zh_TW |
| dc.date.accessioned | 2021-06-17T04:28:28Z | - |
| dc.date.available | 2020-10-05 | |
| dc.date.copyright | 2018-10-05 | |
| dc.date.issued | 2018 | |
| dc.date.submitted | 2018-08-13 | |
| dc.identifier.citation | 衛生福利部國民健康署（2013） 100年版台灣癌症登記摘錄手冊-106年修訂版。取自：http://tcr.cph.ntu.edu.tw/uploadimages/Longform%20Manual_Official% 20version_20171204_Y.pdf 賴裕和（1998） 門診接受化學治療病人之症狀困擾及居家護理需求探討。護理研究，6，279 - 289。 Agaimy, A. (2010). Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting. International Journal of Clinical and Experimental Pathology, 3(5), 461-471. American Joint committee on cancer (AJCC) (2009). American Joint committee on cancer: AJCC releases 7th edition of cancer staging manual. Retrieved form http://www.cancerstaging.org/news/pressrelease 1009.html Antonescu, C. R., Besmer, P., Guo, T., Arkun, K., Hom, G., Koryotowski, B., . . . DeMatteo, R. P. (2005). Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clinical Cancer Research, 11(11), 4182-4190. doi:10.1158/1078-0432.ccr-04-2245 Au, A., Lam, W. W., Kwong, A., Suen, D., Tsang, J., Yeo, W., . . . Fielding, R. (2011). Validation of the Chinese version of the short-form Supportive Care Needs Survey Questionnaire (SCNS-SF34-C). Psychooncology, 20(12), 1292-1300. doi:10.1002/pon.1851 Barnes, T., Reinke, D. (2011). Practical management of imatinib in gastrointestinal stromal tumors. Clin J Oncol Nurs, 15(5), 533-545. doi:10.1188/11.cjon.533-545 Ben Ami, E., Demetri, G. D. (2016). A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor. Expert Opinion on Drug Safety, 15(4), 571-578. doi:10.1517/14740338.2016.1152258 Blanke, C. D., Demetri, G. D., von Mehren, M., Heinrich, M. C., Eisenberg, B., Fletcher, J. A., . . . Joensuu, H. (2008a). Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. Journal of Clinical Oncology, 26(4), 620-625. doi:10.1200/jco.2007.13.4403 Blanke, C. D., Rankin, C., Demetri, G. D., Ryan, C. W., von Mehren, M., Benjamin, R. S., . . . Borden, E. C. (2008b). Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. Journal of Clinical Oncology, 26(4), 626-632. doi:10.1200/jco.2007.13.4452 Boikos, S. A., Pappo, A. S., Killian, J. K., LaQuaglia, M. P., Weldon, C. B., George, S., . . . Helman, L. J. (2016). Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncology, 2(7), 922-928. doi:10.1001/jamaoncol.2016.0256 Bonevski, B., Sanson-Fisher, R., Girgis, A., Burton, L., Cook, P., Boyes, A. (2000). Evaluation of an instrument to assess the needs of patients with cancer. Supportive Care Review Group. Cancer, 88(1), 217-225. Boyes, A., Girgis, A., Lecathelinais, C. (2009). Brief assessment of adult cancer patients' perceived needs: development and validation of the 34-item Supportive Care Needs Survey (SCNS-SF34). Journal of Evaluation in Clinical Practicet, 15(4), 602-606. doi:10.1111/j.1365-2753.2008.01057.x Boyes, A. W., Girgis, A., D'Este, C., Zucca, A. C. (2012). Prevalence and correlates of cancer survivors' supportive care needs 6 months after diagnosis: a population-based cross-sectional study. BMC Cancer, 12, 150. doi:10.1186/1471-2407-12-150 Breccia, M., Efficace, F., Sica, S., Abruzzese, E., Cedrone, M., Turri, D., . . . Alimena, G. (2015). Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leukemia Research, 39(10), 1055-1059. doi:10.1016/j.leukres.2015.07.004 Campbell, H. S., Sanson-Fisher, R., Taylor-Brown, J., Hayward, L., Wang, X. S., Turner, D. (2009). The cancer support person's unmet needs survey: psychometric properties. Cancer, 115(14), 3351-3359. doi:10.1002/cncr.24386 Candelaria, M., de la Garza, J., Duenas-Gonzalez, A. (2005). A clinical and biological overview of gastrointestinal stromal tumors. Medical Oncology, 22(1), 1-10. doi:10.1385/mo:22:1:001 Cella, D., Nowinski, C. J., Frankfurt, O. (2014). The impact of symptom burden on patient quality of life in chronic myeloid leukemia. Oncology, 87(3), 133-147. doi:10.1159/000362816 Chen, M. L., Chang, H. K., Yeh, C. H. (2000). Anxiety and depression in Taiwanese cancer patients with and without pain. Journal of Advanced Nursing, 32(4), 944-951. Chen, P. Y., See, L. C., Wang, C. H., Lai, Y. H., Chang, H. K., Chen, M. L. (1999). The Impact of pain on the anxiety and depression of cancer patients. Journal of the Formosan Medical Association, 3, 373-382. Chen, S. C., Liao, C. T., Lin, C. C., Chang, J. T., Lai, Y. H. (2009). Distress and care needs in newly diagnosed oral cavity cancer patients receiving surgery. Oral Oncology, 45(9), 815-820. Chen, S. C., Lai, Y. H., Liao, C. T., Chang, J. T., Lin, C. Y., Fan, K. H., Huang, B. S. (2013). Supportive care needs in newly diagnosed oral cavity cancer patients receiving radiation therapy. Psychooncology, 22(6), 1220-1228. doi:10.1002/pon.3126 Chambers, S. K., Girgis, A., Occhipinti, S., Hutchison, S., Turner, J., Morris, B., Dunn, J. (2012). Psychological distress and unmet supportive care needs in cancer patients and carers who contact cancer helplines. European Journal of Cancer Care, 21(2), 213-223. doi:10.1111/j.1365-2354.2011.01288.x Corless, C. L., Heinrich, M. C. (2008). Molecular pathobiology of gastrointestinal stromal sarcomas. Annual Review of Pathology, 3, 557-586. doi:10.1146/annurev.pathmechdis.3.121806.151538 Custers, J. A., Tielen, R., Prins, J. B., de Wilt, J. H., Gielissen, M. F., van der Graaf, W. T. (2015). Fear of progression in patients with gastrointestinal stromal tumors (GIST): Is extended lifetime related to the Sword of Damocles? Acta Oncologica, 54(8), 1202-1208. doi:10.3109/0284186x.2014.1003960 Date, R. S., Stylianides, N. A., Pursnani, K. G., Ward, J. B., Mughal, M. M. (2008). Management of gastrointestinal stromal tumours in the Imatinib era: a surgeon's perspective. World Journal of Surgical Oncology, 6, 77-77. doi:10.1186/1477-7819-6-77 Debiec-Rychter, M., Sciot, R., Le Cesne, A., Schlemmer, M., Hohenberger, P., van Oosterom, A. T., . . . Judson, I. (2006). KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. European Journal of Cancer, 42(8), 1093-1103. doi:10.1016/j.ejca.2006.01.030 DeMatteo, R. P., Lewis, J. J., Leung, D., Mudan, S. S., Woodruff, J. M., Brennan, M. F. (2000). Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Annals Surgery, 231(1), 51-58. Demetri, G. D., von Mehren, M., Antonescu, C. R., DeMatteo, R. P., Ganjoo, K. N., Maki, R. G., . . . Wayne, J. D. (2010). NCCN Task Force Report: Update on the Management of Patients with Gastrointestinal Stromal Tumors. Journal of the National Comprehensive Cancer Network, 8(2), S-1-S-41. doi:10.6004/jnccn.2010.0116 Demetri, G. D., von Mehren , M., Blanke , C. D., Van den Abbeele , A. D., Eisenberg , B., Roberts , P. J., . . . Joensuu , H. (2002). Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors. New England Journal of Medicine, 347(7), 472-480. doi:10.1056/NEJMoa020461 Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., . . . Larson, R. A. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New England Journal of Medicine, 355(23), 2408-2417. doi:10.1056/NEJMoa062867 Efficace, F., Baccarani, M., Breccia, M., Cottone, F., Alimena, G., Deliliers, G. L., . . . Mandelli, F. (2013). Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia, 27(7), 1511-1519. doi:10.1038/leu.2013.51 Flynn, K. E., Atallah, E. (2016). Quality of Life and Long-Term Therapy in Patients with Chronic Myeloid Leukemia. Current Hematologic Malignancy Reports, 11(2), 80-85. doi:10.1007/s11899-016-0306-5 Fong, E. J., Cheah, W. L. (2016). Unmet Supportive Care Needs among Breast Cancer Survivors of Community-Based Support Group in Kuching, Sarawak. International Journal of Breast Cancer, 2016, 7297813-729822. doi:10.1155/2016/7297813 Foulon, V., Schoffski, P., Wolter, P. (2011). Patient adherence to oral anticancer drugs: an emerging issue in modern oncology. Acta Clinica Belgica, 66(2), 85-96. doi:10.2143/acb.66.2.2062525 Goetsch, C.M. (2011). Genetic tumor profiling and genetically targeted cancer therapy. Seminars in Oncology Nursing, 27(1), 34-44. Guerin, A., Chen, L., Ionescu-Ittu, R., Marynchenko, M., Nitulescu, R., Hiscock, R., . . . Wu, E. Q. (2014). Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase. Current Medical Research and Opinion, 30(11), 2317-2328. doi:10.1185/03007995.2014.944973 Halfdanarson, T. R., Jatoi, A. (2010). Oral cancer chemotherapy: the critical interplay between patient education and patient safety. Current Oncology Reports, 12(4), 247-252. doi:10.1007/s11912-010-0103-6 Han, Y., Zhou, Y., Wang, J., Zhao, Q., Qin, H., Fan, Y., . . . Cui, S. (2017). Psychometric testing of the Mandarin version of the 34-item Short-Form Supportive Care Needs Survey in patients with cancer in mainland China. Support Care Cancer, 25(11), 3329-3338. doi:10.1007/s00520-017-3750-4 Harrison, J. D., Young, J. M., Price, M. A., Butow, P. N., Solomon, M. J. (2009). What are the unmet supportive care needs of people with cancer? A systematic review. Support Care Cancer, 17(8),1117-1128. doi:10.1007/s00520-009-0615-5 Hassan, I., You, Y. N., Shyyan, R., Dozois, E. J., Smyrk, T. C., Okuno, S. H., . . . Donohue, J. H. (2007). Surgically managed gastrointestinal stromal tumors: a comparative and prognostic analysis. Annals of Surgical Oncology, 15(1), 52-59. doi:10.1245/s10434-007-9633-z Heinrich, M. C., Corless, C. L., Blanke, C. D., Demetri, G. D., Joensuu, H., Roberts, P. J., . . . Fletcher, J. A. (2006). Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. Journal of Clinical Oncology, 24(29), 4764-4774. doi:10.1200/jco.2006.06.2265 Heinrich, M. C., Corless, C. L., Demetri, G. D., Blanke, C. D., Mehren, M. v., Joensuu, H., . . . Fletcher, J. A. (2003). Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 21(23), 4342-4349. doi:10.1200/jco.2003.04.190 Joensuu, H. (2008). Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Human Pathology, 39(10), 1411-1419. doi:10.1016/j.humpath.2008.06.025 Joensuu, H., Eriksson, M., Sundby Hall, K., Hartmann, J. T., Pink, D., Schutte, J., . . . Reichardt, P. (2012). One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. The Journal of the American Medical Association, 307(12), 1265-1272. doi:10.1001/jama.2012.347 Joensuu, H., Rutkowski, P., Nishida, T., Steigen, S. E., Brabec, P., Plank, L., . . . Emile, J. F. (2015). KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence. Journal of Clinical Oncology, 33(6), 634-642. doi:10.1200/jco.2014.57.4970 Joensuu, H., Trent, J. C., Reichardt, P. (2011). Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Cancer Treatment Reviews, 37(1), 75-88. doi:10.1016/j.ctrv.2010.04.008 Joensuu, H., Vehtari, A., Riihimaki, J., Nishida, T., Steigen, S. E., Brabec, P., . . . Rutkowski, P. (2012). Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncology, 13(3), 265-274. doi:10.1016/s1470-2045(11)70299-6 Karnofsky, D. A., Abelmann, W. H. , Craver, L. F. , Burchenal, J. H. (1948). The use of nitrogen mustards in the palliative treatment of cancer. Cancer, 1(4):634-656. Kindblom, L. G., Remotti, H. E., Aldenborg, F., Meis-Kindblom, J. M. (1998). Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. American Journal of Pathology, 152(5), 1259-1269. Lai, Y. H., Chang, J. T., Keefe, F. J., Chiou, C. F., Chen, S. C., Feng, S.C., Liao, M. N. (2003). Symptom distress, catastrophic thinking, and hope in nasopharyngeal carcinoma patients. Cancer Nursing, 26(6), 485-493. Lampic, C., von Essen, L., Peterson, V. W., Larsson, G., Sjoden, P. O. (1996). Anxiety and depression in hospitalized patients with cancer: agreement in patient-staff dyads. Cancer Nursing, 19(6), 419-428. Le Cesne, A., Ray-Coquard, I., Bui, B. N., Adenis, A., Rios, M., Bertucci, F., . . . Blay, J. Y. (2010). Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncology, 11(10), 942-949. doi:10.1016/s1470-2045(10)70222-9 Lee, Y., Wu, Y. S., Chien, C. Y., Fang, F. M., Hung, C. F. (2016). Use of the Hospital Anxiety and Depression Scale and the Taiwanese Depression Questionnaire for screening depression in head and neck cancer patients in Taiwan. Neuropsychiatric Disease and Treatment, 12, 2649-2657. doi:10.2147/NDT.S112069 Li, J., Girgis, A. (2006). Supportive care needs: are patients with lung cancer a neglected population? Psychooncology, 15(6), 509-516. doi:10.1002/pon.983 Liao, Y. C., Liao, W. Y., Shun, S. C., Yu, C. J., Yang, P. C., Lai, Y. H. (2011). Symptoms, psychological distress, and supportive care needs in lung cancer patients. Support Care Cancer, 19(11), 1743-1751. doi:10.1007/s00520-010-1014-7 Li, W. W., Lam, W. W., Au, A. H., Ye, M., Law, W. L., Poon, J., . . . Fielding, R. (2013). Interpreting differences in patterns of supportive care needs between patients with breast cancer and patients with colorectal cancer. Psychooncology, 22(4), 792-798. doi:10.1002/pon.3068 Macdonald, N., Shapiro, A., Bender, C., Paolantonio, M., Coombs, J. (2012). Experiences and perspectives on the GIST patient journey. Patient Preference and Adherence, 6, 253-262. doi:10.2147/PPA.S24617 Mazur, M. T., Clark, H. B. (1983). Gastric stromal tumors. Reappraisal of histogenesis. The American Journal of Surgical Pathology, 7(6), 507-519. McCorkle, R., Young, K. (1978). Development of a symptom distress scale. Cancer Nursing, 1(5), 373-378. McElduff, P., Boyes, A., Zucca, A., Girgis, A. (2004). The Supportive Care Needs Survey: A guide to administration, scoring and analysis. Newcastle: Centre for Health Research Psycho-Oncology. Mehren, M., Joensuu, H. (2017). Gastrointestinal Stromal Tumors. Journal of Clinical Oncology, 36(2), 136-143. Miettinen, M., Lasota, J. (2005). KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Applied Immunohistochemistry Molecular Morphology, 13(3), 205-220. Miettinen, M., Lasota, J. (2006a). Gastrointestinal stromal tumors: pathology and prognosis at different sites. Seminars in Diagnostic Pathology, 23(2), 70-83. Miettinen, M., Lasota, J. (2006b). Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Archives of Pathology Laboratory Medicine, 130(10), 1466-1478. doi:10.1043/1543-2165(2006)130[1466:gstrom]2.0.co;2 Miettinen, M., Makhlouf, H., Sobin, L. H., Lasota, J. (2006). Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. The American Journal of Surgical Pathology, 30(4), 477-489. Miettinen, M., Sarlomo-Rikala, M., Lasota, J. (1999). Gastrointestinal stromal tumors: recent advances in understanding of their biology. Human Pathology, 30(10), 1213-1220. Miettinen, M., Sobin, L. H., Sarlomo-Rikala, M. (2000). Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Modern Pathology, 13(10), 1134-1142. doi:10.1038/modpathol.3880210 Mor, V., Laliberte, L., Morris, J. N., Wiemann, M. (1984). The Karnofsky performance status scale: An examination of its reliability and validity in a research setting. Cancer, 53(9), 2002-2007. National Cancer Institute (2018, Jan 11). NCI Dictionary of Cancer Terms. Retrieved from:https://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid = 450125 Neuss, M. N., Polovich, M., McNiff, K., Esper, P., Gilmore, T. R., LeFebvre, K. B., . . . Jacobson, J. O. (2013). 2013 Updated American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards Including Standards for the Safe Administration and Management of Oral Chemotherapy. Journal of Oncology Practice, 9(2), 5s-13s. doi:10.1200/JOP.2013.000874 Nishida, T., Hirota, S. (2000). Biological and clinical review of stromal tumors in the gastrointestinal tract. Histology and Histopathology, 15(4), 1293-1301. Phillips, K. M., Pinilla-Ibarz, J., Sotomayor, E., Lee, M. R., Jim, H. S., Small, B. J., . . . Jacobsen, P. B. (2013). Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison. Support Care Cancer, 21(4), 1097-1103. doi:10.1007/s00520-012-1630-5 Poort, H., van der Graaf, W. T. A., Tielen, R., Vlenterie, M., Custers, J. A. E., Prins, J. B., . . . Knoop, H. (2016). Prevalence, Impact, and Correlates of Severe Fatigue in Patients With Gastrointestinal Stromal Tumors. Journal of Pain and Symptom Management, 52(2), 265-271. doi:https://doi.org/10.1016/j.jpainsymman.2016.02.019 Sanson-Fisher, R., Girgis, A., Boyes, A., Bonevski, B., Burton, L., Cook, P. (2000). The unmet supportive care needs of patients with cancer. Supportive Care Review Group. Cancer, 88(1), 226-237. Sarkar, S., Sautier, L., Schilling, G., Bokemeyer, C., Koch, U., Mehnert, A. (2015). Anxiety and fear of cancer recurrence and its association with supportive care needs and health-care service utilization in cancer patients. Journal of Cancer Survivorship, 9(4), 567-575. doi:10.1007/s11764-015-0434-2 Schmid-Buchi, S., Halfens, R. J., Muller, M., Dassen, T., van den Borne, B. (2013). Factors associated with supportive care needs of patients under treatment for breast cancer. European Journal of Oncology Nursing, 17(1), 22-29. doi:10.1016/j.ejon.2012.02.003 Simard, S., Thewes, B., Humphris, G., Dixon, M., Hayden, C., Mireskandari, S., Ozakinci, G. (2013). Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. Journal of Cancer Survivorship, 7(3), 300-322. doi:10.1007/s11764-013-0272-z Sklenarova, H., Haun, M. W., Krumpelmann, A., Friederich, H. C., Huber, J., Thomas, M., . . . Hartmann, M. (2015). Psychometric evaluation of the German Version of the Supportive Care Needs Survey for Partners and Caregivers (SCNS-P C-G) of cancer patients. European Journal of Cancer Care, 24(6), 884-897. doi:10.1111/ecc.12325 Sodergren, S. C., White, A., Efficace, F., Sprangers, M., Fitzsimmons, D., Bottomley, A., Johnson, C. D. (2014). Systematic review of the side effects associated with tyrosine kinase inhibitors used in the treatment of gastrointestinal stromal tumours on behalf of the EORTC Quality of Life Group. Critical Reviews in Oncology/Hematology, 91(1), 35-46. doi:10.1016/j.critrevonc.2014.01.002 Soreide, K., Sandvik, O. M., Soreide, J. A., Giljaca, V., Jureckova, A., Bulusu, V. R. (2016). Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemioloogy, 40, 39-46. doi:10.1016/j.canep.2015.10.031 Tamborini, E., Pricl, S., Negri, T., Lagonigro, M. S., Miselli, F., Greco, A., . . . Pilotti, S. (2006). Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene, 25(45), 6140-6146. doi:10.1038/sj.onc.1209639 Thomsen, L., Robinson, T. L., Lee, J. C., Farraway, L. A., Hughes, M. J., Andrews, D. W., Huizinga, J. D. (1998). Interstitial cells of Cajal generate a rhythmic pacemaker current. Nature Medicine, 4(7), 848-851. Verbrugghe, M., Verhaeghe, S., Lauwaert, K., Beeckman, D., Van Hecke, A. (2013). Determinants and associated factors influencing medication adherence and persistence to oral anticancer drugs: a systematic review. Cancer Treatment Reviews, 39(6), 610-621. doi:10.1016/j.ctrv.2012.12.014 Wiener, L., Battles, H., Zadeh, S., Smith, C. J., Helman, L. J., Kim, S. Y. (2012). Gastrointestinal stromal tumor: psychosocial characteristics and considerations. Support Care Cancer, 20(6), 1343-1349. doi:10.1007/s00520-012-1426-7 | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/70451 | - |
| dc.description.abstract | 近年因標靶藥物酪氨酸激酶抑制劑的發明，胃腸道基質瘤病患的存活期大有提升，但長時間或終生服用標靶藥物卻也可能產生問題和需求，目前相關的研究仍有限，故本研究目的在探討接受口服標靶基立克 (Glivec) 治療之胃腸道基質瘤病患的照護需求現況，及其與身體及心理困擾和重要之人口學特質之相關性。 本研究為橫斷式設計，於北部某一所醫學中心的外科門診區進行連續取樣，採用結構式問卷訪談，問卷包含：支持性照護需求調查簡表、症狀嚴重度量表、醫院焦慮憂鬱量表、Karnofsky身體功能狀態量表和疾病基本資料表，收集之資料以敘述性統計、斯皮爾曼相關係數檢定、無母數統計和羅吉斯迴歸進行分析。 本研究符案病人共83位，研究結果顯示口服基立克之胃腸道基質瘤病人整體身體功能良好，症狀平均為輕度至中度嚴重，其中嚴重度最高的前五項為皮膚顏色改變、疲倦、眼眶水腫、睡眠問題和肌肉痙攣; 五大層面之支持性照護需求程度，由高至低為：(1) 健康系統與資訊、(2) 心理、(3) 病人照護及支持、(4) 生理及日常生活、(5) 性需求層面，平均值依序為27.2 (19.3)、18.4 (18.2)、16.4 (16.3)、15.9 (19.0) 和7.7 (20.1)。病人之平均症狀嚴重度、焦慮及憂鬱程度與五大層面照護需求呈現顯著低度至中度相關，進一步以羅吉斯迴歸分析，發現整體支持性照護需求主要的相關因素為憂鬱程度和皮膚顏色改變。 整體而言，使用口服標靶基立克治療之胃腸道基質瘤病人的整體支持性照護需求雖然較其他癌別低，但仍有部分的病人呈現出中高程度照護需求、焦慮和憂鬱的問題，建議未來應於門診篩檢，針對這些病人，發展進一步的介入措施，改善不足之照護需求，以增進病人的生活品質。 | zh_TW |
| dc.description.abstract | Background The advent of oral targeted tyrosine-kinase inhibitor (TKI) therapy, such as Imatinib (Glivec), has made a promising survival for patients with Gastrointestinal Stromal Tumor (GIST). However, patients might suffer from side effects of Imatinib and have supportive care needs. Limited studies have approached this problem. The purposes of this study are to (1) examine levels of supportive care needs; and (2) the relationships between supportive care needs and physical and psychological distress, and selected demographic characteristics in GIST patients taking Imatinib. Method This is a cross-sectional study using consecutive sampling to recruit GIST patients receiving Imatinib therapy in surgical outpatient clinics at a medical center in northern Taiwan. GIST patients were assessed by Supportive Care Needs Survey-Short Form 34 (SCNS-SF34), Symptom Severity Scale (SSS), Hospital Anxiety and Depression Scale (HADS), Karnofsky Performance Status Index (KPS), and background information form. Results A total of 83 patients were recruited in the study. In general, patients reported to have mild to moderate symptoms. The top five symptoms as the descending order of severity were: skin discoloration, fatigue, periorbital edema, sleep problems, and muscle cramp. Patients had low level of unmet supportive care needs. The supportive care need domains as their ranking order were (1) health system and information needs, (2) psychological needs, (3)patient care and support needs, (4) physical and daily living needs, and (5) sexuality needs with mean scores as 27.2 (19.3), 18.4 (18.2), 16.4 (16.3), 15.9 (19.0), and 7.7 (20.1), respectively. Patients with higher symptoms severity, anxiety, and depression revealed higher care needs with generally moderate correlations. Further analysis by logistic regression, we found that depression and skin coloration were those two robust variables related to patients’ overall supportive care needs. Conclusion Although the overall supportive care needs of GIST patients treated with Imatinib are lower than those of other cancer types, some GIST patients are still enduring moderate to high level of unmet care needs, anxiety, and depression. Therefore, we suggest that we should do the screening in outpatient clinics and develop further interventions in order to meet these patients’ unmet care needs. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T04:28:28Z (GMT). No. of bitstreams: 1 ntu-107-R05426017-1.pdf: 2422164 bytes, checksum: 5aaddfa199c53421b82997c905795765 (MD5) Previous issue date: 2018 | en |
| dc.description.tableofcontents | 目錄 謝辭 i 中文摘要 ii Abstract iii 第一章 緒論 1 第一節 研究背景與重要性 1 第二節 研究目的 3 第二章 文獻查證 4 第一節 胃腸道基質瘤疾病簡介與診斷 4 第二節 胃腸道基質瘤治療與存活 10 第三節 胃腸道基質瘤病人之身心困擾 14 第四節 癌症患者的照護需求與因素 17 第三章 研究方法 20 第一節 研究設計 20 第二節 研究架構與操作型定義 21 第三節 研究假設 23 第四節 研究工具 24 第五節 研究流程與倫理考量 27 第六節 資料分析方法 29 第四章 研究結果 30 第一節 人口學特性與疾病治療特性 30 第二節 生理及功能因素與心理因素現況 32 第三節 照護需求現況 34 第四節 照護需求與自變項之相關性及差異分析 36 第五節 照護需求與相關因素 41 第五章 討論 44 第一節 人口學特性、疾病治療特性與照護需求探討 44 第二節 身體活動功能、症狀嚴重程度及心理因素與照護需求探討 46 第三節 照護需求現況探討 49 第六章 結論與建議 51 第一節 結論 51 第二節 研究限制與建議 53 第三節 護理上應用 54 參考文獻 55 | |
| dc.language.iso | zh-TW | |
| dc.subject | 基立克 | zh_TW |
| dc.subject | 照護需求 | zh_TW |
| dc.subject | 症狀 | zh_TW |
| dc.subject | 焦慮 | zh_TW |
| dc.subject | 憂鬱 | zh_TW |
| dc.subject | 胃腸道基質瘤 | zh_TW |
| dc.subject | Care Needs | en |
| dc.subject | Depression | en |
| dc.subject | Imatinib | en |
| dc.subject | Anxiety | en |
| dc.subject | Symptom | en |
| dc.subject | Glivec | en |
| dc.subject | Gastrointestinal Stromal Tumor | en |
| dc.title | 接受口服標靶藥物胃腸道基質瘤患者之照護需求及相關因素探討 | zh_TW |
| dc.title | Care Needs and the Related Factors in Gastrointestinal Stromal Tumor Patients Undergoing Oral Targeted Therapy | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 106-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 楊卿堯,李芸湘 | |
| dc.subject.keyword | 胃腸道基質瘤,基立克,照護需求,症狀,焦慮,憂鬱, | zh_TW |
| dc.subject.keyword | Gastrointestinal Stromal Tumor,Imatinib,Glivec,Care Needs,Symptom,Anxiety,Depression, | en |
| dc.relation.page | 74 | |
| dc.identifier.doi | 10.6342/NTU201803142 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2018-08-13 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 護理學研究所 | zh_TW |
| Appears in Collections: | 護理學系所 | |
Files in This Item:
| File | Size | Format | |
|---|---|---|---|
| ntu-107-1.pdf Restricted Access | 2.37 MB | Adobe PDF |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.